Effect of protein convertase subtilisin/kexin type 9 (PCSK9) 46L gene polymorphism on LDL cholesterol concentration in a Polish adult population

Molecular Genetics and Metabolism

Volumn 94, Issue 2, 2008, Pages 259-262

  Kostrzewa, Grazyna ^a   Broda, Grazyna ^b   Kurjata, Paweł ^b   Piotrowski, Walerian ^b   Ploski, Rafal ^a  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b INSTITUTE OF CARDIOLOGY   (Poland)

Author keywords

Cholesterol; LDL; Myocardial infarction; PCSK9 46L; Polish population; Protein convertase subtilisin kexin type 9; Stroke

Indexed keywords

HYPOCHOLESTEROLEMIC AGENT; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PROTEIN CONVERTASE SUBTILISIN KEXIN 9;

ARTICLE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE PREDISPOSITION; DNA POLYMORPHISM; DRUG EFFECT; HEART INFARCTION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; POPULATION RESEARCH; PRIORITY JOURNAL;

ADULT; AGED; BLOOD; CHOLESTEROL, LDL; CROSS-SECTIONAL STUDIES; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; SERINE ENDOPEPTIDASES; STROKE;

EID: 43249106948     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2008.02.003     Document Type: Article

References (16)

1. Horton J.D., Cohen J.C., and Hobbs H.H. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem. Sci. 32 (2007) 71-77
2. Lambert G. Unravelling the functional significance of PCSK9. Curr. Opin. Lipidol. 18 (2007) 304-309
3. Cohen J., Pertsemlidis A., Kotowski I.K., Graham R., Garcia C.K., and Hobbs H.H. Low LDL cholesterol in individuals of African descent resulting from frequent nonsense mutations in PCSK9. Nat. Genet. 37 (2005) 161-165
4. Cohen J.C., Boerwinkle E., Mosley Jr. T.H., and Hobbs H.H. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med. 354 (2006) 1264-1272
5. Berge K.E., Ose L., and Leren T.P. Missense mutations in the PCSK9 gene are associated with hypocholesterolemia and possibly increased response to statin therapy. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 1094-1100
6. Hallman D.M., Srinivasan S.R., Chen W., Boerwinkle E., and Berenson G.S. Relation of PCSK9 mutations to serum low-density lipoprotein cholesterol in childhood and adulthood (from The Bogalusa Heart Study). Am. J. Cardiol. 100 (2007) 69-72
7. Kotowski I.K., Pertsemlidis A., Luke A., Cooper R.S., Vega G.L., Cohen J.C., and Hobbs H.H. A spectrum of PCSK9 alleles contributes to plasma levels of low-density lipoprotein cholesterol. Am. J. Hum. Genet. 78 (2006) 410-422
8. Scartezini M., Hubbart C., Whittall R.A., Cooper J.A., Neil A.H., and Humphries S.E. The PCSK9 gene R46L variant is associated with lower plasma lipid levels and cardiovascular risk in UK healthy men. Clin. Sci. (Lond.) 113 (2007) 435-441
9. Rywik S., Kupsc W., Piotrowski W., and Broda G. Multi-Center All-Polish Health Survey-WOBASZ Project. Methodological assumptions and logistics. Pol. Popul. Rev. 27 (2005) 37-50
10. Broda G., and Rywik S. Multi-Center All-Polish Health Survey-WOBASZ Project. Defining the problem and aims of the study. Pol. Popul. Rev. 27 (2005) 29-36
11. Benjannet S., Rhainds D., Hamelin J., Nassoury N., and Seidah N.G. The proprotein convertase (PC) PCSK9 is inactivated by furin and/or PC5/6A: functional consequences of natural mutations and post-translational modifications. J. Biol. Chem. 281 (2006) 30561-30572
12. Olsen T.S., Christensen R.H.B., Kammersgaard L.P., and Andersen K.K. Higher total serum cholesterol levels are associated with less severe strokes and lower all-cause mortality: ten-year follow-up of ischemic strokes in the Copenhagen Stroke Study. Stroke 38 (2007) 2646-2651
13. Bowman T.S., Sesso H.D., Ma J., Kurth T., Kase C.S., Stampfer M.J., and Gaziano J.M. Cholesterol and the risk of ischemic stroke. Stroke 34 (2003) 2930-2934
14. Prospective studies collaboration, Cholesterol, diastolic blood pressure, and stroke: 13,000 strokes in 450,000 people in 45 prospective cohorts. Prospective studies collaboration, Lancet 346 (1995) 1647-1653.
15. Iso H., Jacobs Jr. D.R., Wentworth D., Neaton J.D., and Cohen J.D. Serum cholesterol levels and six-year mortality from stroke in 350,977 men screened for the multiple risk factor intervention trial. N. Engl. J. Med 320 (1989) 904-910
16. Kagan A., Popper J.S., and Rhoads G.G. Factors related to stroke incidence in Hawaii Japanese men. The Honolulu Heart Study. Stroke 11 (1980) 14-21